Patient Reported Outcomes in Chronic Inflammatory Diseases: Current State, Limitations and Perspectives

Abstract

Chronic inflammatory diseases (CID) are emerging disorders which do not only affect specific organs with respective clinical symptoms but can also affect various aspects of life, such as emotional distress, anxiety, fatigue and quality of life. These facets of chronic disease are often not recognized in the therapy of CID patients. Furthermore, the symptoms and patient-reported outcomes often do not correlate well with the actual inflammatory burden. The discrepancy between patient-reported symptoms and objectively assessed disease activity can indeed be instructive for the treating physician to draw an integrative picture of an individual’s disease course. This poses a challenge for the design of novel, more comprehensive disease assessments. In this mini-review, we report on the currently available patient-reported outcomes, the unmet needs in the field of chronic inflammatory diseases and the challenges of addressing these.

The Mediating and Moderating Role of Resilience Between Stigma and Illness Identity Among People with Inflammatory Bowel Disease

“… 7 The suffering caused by disease progression, the adverse side effects associated with clinical treatment(eg, impaired body image and impaired fertility), and the high cost of medical care impose a heavy physical and mental burden on patients. 8 , 9 …”

Impact of regular cold exposure on electrical skin resistance in patients with joint degenerative diseases

“…Chronic inflammatory diseases (CID) are often diagnosed in 80−90% of older people and are considered to be age-related diseases (Tran et al, 2021). CID cover systemic inflammatory diseases including joint degenerative diseases notably Rheumatoid Arthritis, Osteoarthritis, Infectious Arthritis, Ankylosing Spondylitis (Heap & van Heel, 2009).…”

Effect of risankizumab on health‐related quality of life in patients with Crohn's disease: results from phase 3 MOTIVATE, ADVANCE and FORTIFY clinical trials

“…These measures aid in identifying an individual patient's illness perceptions, are strongly associated with the patient's quality of life, and foster shared decision-making between patients and physicians, which is required for the successful long-term management of Crohn's disease. [14][15][16] Risankizumab, a humanised immunoglobulin G1 monoclonal antibody directed against interleukin-23 p19, is currently being investigated in the treatment of Crohn's disease. Primary clinical and endoscopic results of the phase 3 induction (ADVANCE and MOTIVATE) and maintenance (FORTIFY) studies have been reported.…”

“…Beyond mucosal healing, patient‐reported outcomes are becoming important measures to assess the benefit of treatment in Crohn's disease. These measures aid in identifying an individual patient's illness perceptions, are strongly associated with the patient's quality of life, and foster shared decision‐making between patients and physicians, which is required for the successful long‐term management of Crohn's disease 14–16 …”